Comprehensive coverage on the latest pharmaceutical regulatory update and industry activities in China.
Marketing Approval Priority Review and Approval Innovative Drugs Generic Drugs Drug Registration New DrugsMonthly Report: New Drug Approvals in China | Aug. 2021 In Aug. 2021, China NMPA nodded for nine new drug products including Tislelizumab Injection, Apremilast Tablet and Nivolumab Injection.
Sep 14, 2021
China Releases Second Batch of 17 Encouraged Generic Drugs China officially issued the Second Batch of 17 Encouraged Generic Drugs, which could benefit from preferential policy support in terms of priority review and approval, clinical trials and critical generic technology researches in China.
Mar 26, 2021
In Light of the 14th Rare Disease Day, How Is China Doing on Rare Disease Drugs? On February 28, 2021, the international community observes the 14th Rare Disease Day, which is a time of the year to raise awareness among the general public and to also reflect upon the progress of orphan drugs development.
Mar 08, 2021
China CDE to Disclose New Drugs' Technical Review Reports China's Center of Drug Evaluation (CDE) recently announced that it would disclose the technical review reports and package inserts of all new drugs approved since Sept. 1, 2016. The disclosure would also extend to generic drugs and other applications in the future.
Feb 24, 2021
China Releases Draft List of Second Batch of Encouraged Generic Medicines On Dec. 30, 2020, China National Health Commission issued the Draft List of Second Batch of 19 Generic Medicines, encouraging pharmaceutical firms to develop and produce them. Medicines for chronic obstructive pulmonary disease and asthma are included in the list.
Dec 31, 2020
- Monthly Recap: China Pharmaceutical Regulatory Updates | July 2021
- Expedited Programs for Drug Registration in China
- China Rolls Out Measures to Establish Drug Patent Linkage System
- China Drug Evaluation Report 2020-Reform of Drug Review & Approval System
- Monthly Report: New Drug Approvals in China | July 2021